Recent advances of highly selective CDK4/6 inhibitors in breast cancer

Recent advances of highly selective CDK4/6 inhibitors in breast cancer

Abstract Uncontrolled cell division is the hallmark of cancers. Full understanding of cell cycle regulation would contribute to promising cancer therapies. In particular, cyclin-dependent kinases 4/6 (CDK4/6), which are pivotal drivers of cell proliferation by combination with cyclin D, draw more an...

Full description

Bibliographic Details
Main Authors: Hanxiao Xu, Shengnan Yu, Qian Liu, Xun Yuan, Sridhar Mani, Richard G. Pestell, Kongming Wu
Format: Article
Language:English
Published: BMC 2017-04-01
Series:Journal of Hematology & Oncology
Subjects:
Breast cancer
CDK4/6 inhibitors
Palbociclib
Ribociclib
Abemaciclib
Safety
Online Access:http://link.springer.com/article/10.1186/s13045-017-0467-2

Similar Items

Similar Items